|Bid||9.10 x 0|
|Ask||9.12 x 0|
|Day's Range||9.10 - 9.44|
|52 Week Range||4.76 - 22.00|
|Beta (3Y Monthly)||4.03|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.61|
On June 18, Canaccord Genuity cut its target price on Aphria (APHA) to 16 Canadian dollars from 18 Canadian dollars. Canaccord also lowered its revenue estimates for the company.
Aphria's valuation has taken a beating. The company came under fire from short sellers due to its investment activities in Latin America. Aphria's valuation multiples have been diverging from the peer median.
On June 24, Aphria stock rose ~5.7% without any visible catalyst. The company's valuations are at an all-time low compared to its peers, which might have attracted value buyers to the stock.
So far, Cronos Group (CRON) has delivered a 13% return in June. The company struggled to remain in the positive territory in the previous three months due to its high valuation.
The cannabis sector's current forward EV-to-EBITDA multiple is trading at a median of 19x, which has largely moved sideways over the past few months. Investors have less confidence in the cannabis sector.
Cannabis sector stocks haven't risen in the past three months due to disappointing earnings, which largely missed the expectations. Investors hoped that the companies would post huge sales figures.
Aphria Inc (TSX:APHA)(NYSE:APHA) might not see $20 again for quite some time, but that doesn't mean you should overlook this controversial name.
Canada’s leading marijuana producer Canopy Growth said shareholders approved its deal to acquire the American cannabis chain Acreage Holdings — if the U.S. legalizes marijuana federally.
Shoppers Drug Mart is partnering with TruTrace Technologies Inc. to bolster its medical cannabis retail platform.
The sentiment towards the cannabis sector weakened further last week, as major industry players ended in the negative territory. HEXO (HEXO), which released disappointing earnings on June 12, was one of the key reasons for the extension of the weakness in the sector last week.
The slow takeoff of recreational marijuana sales in Canada was expected to gain speed when Canada planned to allow sales of vapes, edibles, beverages, and the popular CBD. Now that’s been delayed.
Aphria Inc. (TSX:APHA)(NYSE:APHA) is back in the thick of the action. The third-largest cannabis producer has good chances of snatching the leadership position from the industry giant.
Tilray Inc. (NASDAQ:TLRY) and Aphria Inc (TSX:APHA)(NYSE:APHA) are two marijuana stocks that you shouldn't buy unless you have a higher risk appetite.
After a solid few years, marijuana stocks like Aphria Inc (TSX:APHA)(NYSE:APHA) could collapse in the second half of 2019.